Diligence memo · auto-generated · as of July 2, 2026
Immunostics, Inc.
Immunostics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Immunostics, Inc. operates in Other Health Care, based in OCEAN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immunostics, Inc. has raised $3.7M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2016-12-12.
Most recent recorded round closed around 2016-12-12.
Valuation (modeled)modeled
Provath models Immunostics, Inc. at approximately $74M (range $2.5M–$583M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.68× the median modeled value of Seed Other Health Care companies in 2016–2018 (222 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 3 months.
Last raise 9.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 59% of Other Health Care peers (5377 compared).
Modeled value ranks above 74% of those peers.
Closest niche peers: Eye Academy of America Ltd., Ruddco Inc., Guest House Holdings, LLC, Cb Therapeutics Inc., Shift Sciences, LLC.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.